A Phase 2 Study to Evaluate Immune Responses of FluMist®

Completed · Phase 2

Conditions studied: Influenza Vaccine

In brief

The primary objective of this study is to describe the level of serum antibody and cellular immune responses conferred by FluMist and TIV against influenza virus strains.

Key facts

Study ID

NCT00461981

Run by

MedImmune LLC

People needed

101

Starts

2007-05-01

Expected to finish

2008-02-01

Last updated by the study team

2021-10-06

Who can join

Age: 1 and older, up to 3. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Male or female aged 12 to <36 months (reached their 1st year but not yet reached their 3rd year birthday) at the time of randomization
• Written informed consent and HIPAA authorization obtained from the subject's legal representative
• Ability of the subject's legal representative to understand and comply with the requirements of the study
• Subject's legal representative available by telephone
• Ability to complete follow-up period of 180 days after final study vaccination as required by the protocol

You may not qualify if…

• History of hypersensitivity to any component of FluMist or TIV, including egg or egg products
• History of hypersensitivity to gentamicin
• Any known immunosuppressive condition or immune deficiency disease (including HIV infection), or ongoing receipt of any immunosuppressive therapy
• Household contact who is immunocompromised (participants should also avoid close contact with immunocompromised individuals for at least 21 days after each study vaccination)
• History of Guillain-Barré syndrome
• Any prior history of wheezing or asthma
• Acute febrile (≥100.0°F oral or equivalent) and/or clinically significant respiratory illness (e.g., cough or sore throat) within 72 hours prior to either study vaccination
• Use of aspirin or aspirin-containing products within the 30 days prior to randomization, or expected receipt through 180 days after final study vaccination
• Receipt of any prior influenza vaccine
• Use of anti-influenza medications (including amantadine, rimantadine, oseltamivir, and zanamivir) within 14 days prior to randomization, or expected receipt through 35 days after final study vaccination
• Administration of any live virus vaccine, other than measles, mumps, rubella, and varicella-containing vaccine(s), within 30 days prior to randomization, or expected receipt through 30 days after final study vaccination
• Administration of any inactivated (i.e., non-live) vaccine within 14 days prior to randomization, or expected receipt within 14 days before or 14 days after either study vaccination
• Receipt of any investigational agent within 30 days prior to randomization, or expected receipt through 180 days after final study vaccination (use of licensed agents for indications not listed in the package insert is permitted)
• Receipt of any blood product within 90 days prior to randomization, or expected receipt through 35 days after final study vaccination
• Family member or household contact who is an employee of the research center or otherwise involved with the conduct of the study
• Any condition that in the opinion of the investigator would interfere with evaluation of the vaccine or interpretation of study results

Where it is running

• Harvey Pediatrics — Jonesboro, Arkansas, United States
• Arkansas Pediatric Clinic — Little Rock, Arkansas, United States
• NuLife Clinical Research — Anaheim, California, United States
• Palm Beach Research Center — West Palm Beach, Florida, United States
• Central Kentucky Research Associates — Lexington, Kentucky, United States
• Peak Medical Research, LLC — Owensboro, Kentucky, United States
• Benchmark Research — Metairie, Louisiana, United States
• Meridian Clinical Research, LLC — Omaha, Nebraska, United States
• Henderson Pediatrics — Henderson, Nevada, United States
• Regional Clinical Research, Inc. — Endwell, New York, United States
• Dayton Clinical Research — Dayton, Ohio, United States
• Northeast Cincinnati Pediatric Asso., Inc. — Mason, Ohio, United States
• Celia Reyes-Acuna, M.D. — Corpus Christi, Texas, United States
• Allergy Immunology Research Center of North Texas — Dallas, Texas, United States
• Healthcare Discoveries, Inc. — San Antonio, Texas, United States
• Wee Care Pediatrics — Layton, Utah, United States
• Bear Care Pediatrics — Ogden, Utah, United States
• Advanced Pediatrics — Vienna, Virginia, United States
• Pediatrics at the Beach — Virginia Beach, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.